尿液中NMP22作为膀胱癌新标志物的初步评价

目的：探讨NMP22对膀胱癌临床诊断的价值。方法：应用酶联免疫法检测20例膀胱癌术前，12例膀胱癌术后，20例良性泌尿系疾病及20例正常健康志愿者尿液中的NMP22的含量。结果：把阳性临界值设置在10u/ml，膀胱癌术前尿NMP22中位数为39．03u/ml，阳性率为80％，而术后尿NMP22中位数为9．27u/ml，其与病理分级，临床分期无明显相关性；良性泌尿系疾病尿NMP22中位数为5．77u/ml，阳性率30％，正常健康志愿者尿NMP22中位数为2．82u/ml，都为阴性，膀胱癌患者尿NMP22中位数显著高于良性泌尿系疾病患者尿NMP22中位数（P＜0．01，单尾秩和检验）。结论：NMP22是监测膀胱癌的有效标志物。

Evaluation of urinary NMP22 as a new marker in detection of bladder cancer

Objective: To assess the clinical diagnostic value of NMP22 for bladder cancer. Methods: The urine samples of 20 cases before the resection of bladder cancer,12 cases after the resection of bladder cancer,20 cases with benign urinary tract conditions and 20 cases normal healthy volunteers were examined using ELISA.Results: When the cut-off was set 10u/ml,the median levels of urinary NMP22 for those who hadn't received the resection of bladder cancer was 39.03u/ml, the positive rate was 80%,and for those who had received the resection of bladder cancer was 9.27u/ml.The level of urinary NMP22 was not associated with the pathological grade and clinical stage.The median urinary NMP22 levels in the patients with benign urinary tract conditions was 5.77u/ml,and the positive rate was 30%.The levels of urinary NMP22 for normal healthy volunteers was 2.82u/ml, and the results were all negative. The median levels of urinary NMP22 in the patients with bladder cancer was significantly greater than that in the patients with benign urinary tract conditions(P<0.01,1-tailed Mann-Whitney test). Conclusion: NMP22 is a promising tumor marker for monitoring bladder cancer.